---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-017422"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:21:40.364276+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 selectively kills triple-negative breast cancer cells in lab studies

## Summary
- Telomir-1 produced concentration-dependent reduction in TNBC cell survival; iron addition reversed effect, confirming iron-dependent mechanism.
- Compound targets aggressive TNBC cells' metabolic reliance on iron, potentially sparing healthy tissue due to differing iron management.
- Findings link Telomir-1's effect to Jumonji domain histone demethylases (KDM5A/B, KDM6B) involved in cancer aggression and therapy resistance.
- Company plans to expand studies to pancreatic and leukemia models, and conduct animal studies ahead of IND submission.

## SEC filing metadata
- accession: 0001493152-25-017422
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225017422/0001493152-25-017422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225017422/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-017422
- JSON: https://secwatch.observer/filing/0001493152-25-017422.json
- Plain text: https://secwatch.observer/filing/0001493152-25-017422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.